Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2016 | Apr. 18, 2016 | |
Document And Entity Information [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Mar. 31, 2016 | |
Document Fiscal Year Focus | 2,016 | |
Document Fiscal Period Focus | Q1 | |
Trading Symbol | CEMP | |
Entity Registrant Name | CEMPRA, INC. | |
Entity Central Index Key | 1,461,993 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Large Accelerated Filer | |
Entity Common Stock, Shares Outstanding | 48,200,550 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2016 | Dec. 31, 2015 |
Current assets | ||
Cash and equivalents | $ 223,609 | $ 153,765 |
Receivables | 3,846 | 7,639 |
Prepaid expenses | 1,241 | 573 |
Total current assets | 228,696 | 161,977 |
Furniture, fixtures and equipment, net | 75 | 90 |
Deposits | 152 | 73 |
Total assets | 228,923 | 162,140 |
Current liabilities | ||
Accounts payable | 11,192 | 9,635 |
Accrued expenses | 993 | 1,475 |
Accrued payroll and benefits | 1,051 | 2,337 |
Current portion of long-term debt | 6,111 | 4,444 |
Total current liabilities | 19,347 | 17,891 |
Deferred revenue | 11,326 | 11,326 |
Long-term debt | 13,606 | 15,258 |
Total liabilities | $ 44,279 | $ 44,475 |
Commitments and contingencies | ||
Shareholders' Equity | ||
Preferred stock; $.001 par value; 5,000,000 shares authorized; no shares issued or outstanding at March 31, 2016 and December 31, 2015 | ||
Common stock; $.001 par value; 80,000,000 shares authorized; 48,193,181 and 43,990,751 issued and outstanding at March 31, 2016 and December 31, 2015, respectively | $ 48 | $ 44 |
Additional paid-in capital | 533,024 | 436,643 |
Accumulated deficit | (348,428) | (319,022) |
Total shareholders’ equity | 184,644 | 117,665 |
Total liabilities and shareholders’ equity | $ 228,923 | $ 162,140 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares | Mar. 31, 2016 | Dec. 31, 2015 |
Statement Of Financial Position [Abstract] | ||
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 5,000,000 | 5,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 80,000,000 | 80,000,000 |
Common stock, shares issued | 48,193,181 | 43,990,751 |
Common stock, shares outstanding | 48,193,181 | 43,990,751 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2016 | Mar. 31, 2015 | |
Revenue | ||
Contract research | $ 2,679 | $ 2,077 |
License | 10,000 | |
Supply | 1,887 | |
Total revenue | 2,679 | 13,964 |
Operating expenses | ||
Research and development | 23,529 | 26,118 |
General and administrative | 8,324 | 4,650 |
Total operating expenses | 31,853 | 30,768 |
Loss from operations | (29,174) | (16,804) |
Other income (expense) | ||
Interest income | 98 | 2 |
Interest expense | (330) | (614) |
Other income (expense), net | (232) | (612) |
Net loss and comprehensive loss | $ (29,406) | $ (17,416) |
Basic and diluted net loss attributable to common shareholders per share | $ (0.61) | $ (0.41) |
Basic and diluted weighted average shares outstanding | 47,853,099 | 42,670,632 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 3 Months Ended | |
Mar. 31, 2016 | Mar. 31, 2015 | |
Operating activities | ||
Net loss | $ (29,406,000) | $ (17,416,000) |
Adjustments to reconcile net loss to net cash used in operating activities | ||
Depreciation | 14,858 | 18,158 |
Share-based compensation | 2,365,000 | 1,435,000 |
Amortization of debt issuance costs | 15,000 | 184,000 |
Changes in operating assets and liabilities | ||
Receivables | 3,793,000 | (11,868,000) |
Prepaid expenses | (668,000) | 870,000 |
Deposits | (79,000) | |
Accounts payable | 1,557,000 | (1,042,000) |
Accrued expenses | (482,000) | (478,000) |
Accrued payroll and benefits | (1,286,000) | (1,032,000) |
Net cash used in operating activities | (24,176,000) | (29,329,000) |
Investing activities | ||
Purchases of furniture, fixtures and equipment | (46,000) | |
Net cash used in investing activities | (46,000) | |
Financing activities | ||
Proceeds from exercise of stock options and warrants | 239,000 | 549,000 |
Proceeds from issuance of common stock, net of underwriting discounts | 94,000,000 | 139,044,000 |
Payment of offering costs | (219,000) | (213,000) |
Net cash provided by financing activities | 94,020,000 | 139,380,000 |
Net change in cash and equivalents | 69,844,000 | 110,005,000 |
Cash and equivalents at beginning of the period | 153,765,000 | 99,113,000 |
Cash and equivalents at end of the period | 223,609,000 | 209,118,000 |
Supplemental cash flow information | ||
Cash paid for interest | $ 322,000 | $ 430,000 |
Description of Business
Description of Business | 3 Months Ended |
Mar. 31, 2016 | |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |
Description of Business | 1. Description of Business Cempra, Inc. (the “Company” or “Cempra”) is the successor entity of Cempra Pharmaceuticals, Inc. which was incorporated on November 18, 2005 and commenced operations in January 2006. Cempra is located in Chapel Hill, North Carolina, and is a pharmaceutical company developing antibiotics to treat drug-resistant bacterial infections in the hospital and community. The Company expects to continue to incur losses and require additional financial resources to advance its products to either commercial stage or liquidity events. There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations and financial condition. |
Basis of Presentation
Basis of Presentation | 3 Months Ended |
Mar. 31, 2016 | |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |
Basis of Presentation | 2. Basis of Presentation Principles of Consolidation and Basis of Presentation The accompanying consolidated financial statements include the accounts and results of operations of Cempra and its wholly owned subsidiaries. The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany balances and transactions have been eliminated in consolidation. Unaudited Interim Financial Data The accompanying interim consolidated financial statements are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the accompanying notes for the year ended December 31, 2015 contained in the Company’s Annual Report on Form 10-K. The unaudited interim consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of March 31, 2016 and the results of operations and cash flows for the three months ended March 31, 2016 and 2015. The December 31, 2015 consolidated balance sheet included herein was derived from audited consolidated financial statements, but does not include all disclosures including notes required by U.S. GAAP for complete financial statements. Use of Estimates The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Receivables Receivables consist of amounts billed and amounts earned but unbilled under the Company’s contract with the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services (“BARDA”). Receivables under the BARDA contract are recorded as qualifying research activities are conducted and invoices from the Company’s vendors are received. Unbilled receivables are also recorded based upon work estimated to be complete for which the Company has not received vendor invoices. The Company carries its accounts receivable at cost less an allowance for doubtful accounts. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance based on its history of collections and write-offs and the current status of all receivables. The Company does not accrue interest on trade receivables. If accounts become uncollectible, they will be written off through a charge to the allowance for doubtful accounts. The Company has not recorded an allowance for doubtful accounts as management believes all receivables are fully collectible. Research and Development Expenses Research and development (“R&D”) expenses include direct and indirect R&D costs. Direct R&D consists principally of external costs, such as fees paid to investigators, consultants, central laboratories and clinical research organizations, including costs incurred in connection with clinical trials, and related clinical trial fees and all employee-related expenses for those employees working in research and development functions, including stock-based compensation for R&D personnel. Indirect R&D costs include insurance or other indirect costs related to the Company’s research and development function to specific product candidates. R&D costs are expensed as incurred. Expenses paid but not yet incurred are recorded in prepaid expenses. The Company expenses pre-approval inventory as R&D until regulatory approval is received. Clinical Trial Accruals As part of the process of preparing financial statements, the Company is required to estimate its expenses resulting from its obligation under contracts with vendors and consultants and clinical site agreements in connection with conducting clinical trials. The Company’s objective is to reflect the appropriate clinical trial expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. The Company determines accrual estimates through discussion with applicable personnel and outside service providers as to the progress of trials or the services completed. During the course of a clinical trial, the Company adjusts its rate of clinical trial expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. The Company’s clinical trial accrual is dependent upon the timely and accurate reporting of fee billings and passthrough expenses from contract research organizations and other third-party vendors as well as the timely processing of any change orders from the contract research organizations. Revenue Recognition The Company’s revenue generally consists of research related revenue under federal contracts and licensing revenue related to non-refundable upfront fees, milestone payments and royalties earned under license agreements. Revenue is recognized when the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products and/or services has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured. For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has “stand-alone value” to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling prices of each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods and services are delivered, limited to the consideration that is not contingent upon future deliverables. When an arrangement is accounted for as a single unit of accounting, the Company determines the period over which the performance obligations will be performed and revenue recognized. Milestone payments are recognized when earned, provided that (i) the milestone event is substantive; (ii) there is no ongoing performance obligation related to the achievement of the milestone earned; and (iii) it would result in additional payments. Milestone payments are considered substantive if all of the following conditions are met: the milestone payment is non-refundable; achievement of the milestone was not reasonably assured at the inception of the arrangement; substantive effort is involved to achieve the milestone; and the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement, and the related risk associated with the achievement of the milestone. Contingent-based payments the Company may receive under a license agreement will be recognized when received. Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2016-09, Compensation-Stock Compensation. The new guidance simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. This guidance is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers. This guidance clarifies the implementation guidance on principal versus agent considerations. This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2017, which is effective for the Company for the year ending December 31, 2018. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s financial statements. In February 2016, the FASB issued ASU 2016-02, Leases. The new guidance will increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers. This new guidance clarifies the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The guidance outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes the most current revenue recognition guidance. This guidance, as amended by ASU 2015-14, is effective for fiscal years and interim periods within those years beginning after December 15, 2017, which is effective for the Company for the year ending December 31, 2018. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s financial statements. |
Fair Value of Financial Instrum
Fair Value of Financial Instruments | 3 Months Ended |
Mar. 31, 2016 | |
Fair Value Disclosures [Abstract] | |
Fair Value of Financial Instruments | 3. Fair Value of Financial Instruments The carrying values of cash and equivalents, receivables, prepaid expenses, and accounts payable at March 31, 2016 approximated their fair values due to the short-term nature of these items. The Company’s valuation of financial instruments is based on a three-tiered approach, which requires that fair value measurements be classified and disclosed in one of three tiers. These tiers are: Level 1, defined as quoted prices in active markets for identical assets or liabilities; Level 2, defined as valuations based on observable inputs other than those included in Level 1, such as quoted prices for similar assets and liabilities in active markets, or other inputs that are observable or can be corroborated by observable input data; and Level 3, defined as valuations based on unobservable inputs reflecting the Company’s own assumptions, consistent with reasonably available assumptions made by other market participants. At March 31, 2016 and December 31, 2015, the Company held money market funds classified as Level 1 financial instruments of $223.6 million and $129.0 million, respectively. The Term Loan (defined and discussed in Note 9), which is classified as a Level 2 liability, has a variable interest rate and, accordingly, its carrying value approximates its fair value. At March 31, 2016, the carrying value was $19.7 million. There were no transfers between levels of the fair value hierarchy for any assets or liabilities measured at fair value in the three months ended March 31, 2016. |
Significant Agreements and Cont
Significant Agreements and Contracts | 3 Months Ended |
Mar. 31, 2016 | |
Significant Agreements And Contracts [Abstract] | |
Significant Agreements and Contracts | 4. Significant Agreements and Contracts License Agreements Optimer Pharmaceuticals, Inc. In March 2006, the Company, through its wholly owned subsidiary, Cempra Pharmaceuticals, Inc., entered into a Collaborative Research and Development and License Agreement (“Optimer Agreement”) with Optimer Pharmaceuticals, Inc. (“Optimer”) which was acquired by Cubist Pharmaceuticals, Inc. in October 2013, which was in turn acquired by Merck in January 2015. Under the terms of the Optimer Agreement, the Company acquired exclusive rights to further develop and commercialize certain Optimer technology worldwide, excluding member nations of the Association of Southeast Asian Nations (“ASEAN”). Optimer was acquired by Cubist Pharmaceuticals, Inc. in October 2013, which was in turn acquired by Merck in January 2015. In exchange for this license, during 2006 and 2007, the Company issued an aggregate of 125,646 common shares with a total fair value of $190,418 to Optimer. These issuances to Optimer were expensed as incurred in research and development expense. In July 2010, the Company paid a $500,000 milestone payment to Optimer after the successful completion of its first solithromycin Phase 1 program. In July 2012, the Company paid a $1,000,000 milestone after the successful completion of its first solithromycin Phase 2 program. Both milestones were expensed as incurred in research and development expense. Under the terms of the Optimer Agreement, the Company will owe Optimer additional payments, contingent upon the achievement of various development, regulatory and commercialization milestone events. The aggregate amount of such milestone payments the Company may need to pay is based in part on the number of products developed under the agreement and would total $27,500,000 (including the two milestone payments made to date) if four products are developed and gain FDA approval. The Company will also pay tiered mid-single-digit royalties based on the amount of annual net sales of its approved products. The Scripps Research Institute In June 2012, the Company entered into a license agreement with The Scripps Research Institute (“TSRI”), whereby TSRI licensed to the Company rights, with rights of sublicense, to make, use, sell, and import products for human or animal therapeutic use that use or incorporate one or more macrolides as an active pharmaceutical ingredient and is covered by certain patent rights owned by TSRI claiming technology related to copper-catalysed ligation of azides and acetylenes. The rights licensed to the Company are exclusive as to the People’s Republic of China (excluding Hong Kong), South Korea and Australia, and are non-exclusive in all other countries worldwide, except ASEAN member-nations, which are not included in the territory of the license. Under the terms of the agreement with TSRI, the Company paid a one-time only, non-refundable license issue fee in the amount of $350,000 which was charged to research and development expense in the second quarter of 2012. The Company is also obligated to pay annual maintenance fees to TSRI in the amount of (i) $50,000 each year for the first three years (beginning on the first anniversary of the agreement), and (ii) $85,000 each year thereafter (beginning on the fourth anniversary of the agreement). Each calendar year’s annual maintenance fees will be credited against sales royalties due under the agreement for such calendar year. Under the terms of the agreement, the Company must pay TSRI low single-digit percentage royalties on the net sales of the products covered by the TSRI patents for the life of the TSRI patents, a low single-digit percentage of non-royalty sublicensing revenue received with respect to countries in the nonexclusive territory and a mid-single-digit percentage of sublicensing revenue received with respect to countries in the exclusive territory, with the sublicensing revenue royalty in the exclusive territory and the sales royalties subject to certain reductions under certain circumstances. TSRI is eligible to receive milestone payments of up to $1.1 million with respect to regulatory approval in the exclusive territory and first commercial sale, in each of the exclusive territory and nonexclusive territory, of the first licensed product to achieve those milestones that is based upon each macrolide covered by the licensed patents. Each milestone is payable once per each macrolide. Each milestone payment made to TSRI with respect to a particular milestone will be creditable against any payment due to TSRI with respect to any sublicense revenues received in connection with the achievement of such milestone. Pursuant to the terms of the Optimer Agreement, any payments made to TSRI under this license for territories subject to the Optimer Agreement can be deducted from any sales-based royalty payments due under the Optimer Agreement up to a certain percentage reduction of the royalties due to Optimer. Under the terms of the agreement, the Company is also required to pay additional fees on royalties, sublicensing and milestone payments if the Company, an affiliate with the Company, or a sub licensee challenges the validity or enforceability of any of the patents licensed under the agreement. Such increased payments would be required until all patent claims subject to challenge are invalidated in the particular country where such challenge was mounted. License and milestone payments received under the license agreement with Toyama (discussed below), have resulted in $200,000 of fees paid to TSRI as of March 31, 2016. The term of the license agreement (and the period during which we must pay royalties to TSRI in a particular country for a particular product) will end, on a country-by-country and product-by-product basis, at such time as no patent rights licensed from TSRI cover a particular product in the particular country. TSRI may terminate the agreement in the event (i) we fail to cure any non-payment or default on our indemnity or insurance obligations, (ii) we declare insolvency or bankruptcy, (iii) if we are convicted of a felony relating to the development, manufacture, use, marketing, distribution or sale of any products licensed under the agreement, (iv) we fail to cure any underreporting or underpayment by a certain amount in any 12-month period, or (v) we fail to cure any default on any other obligation under the agreement. We may terminate the agreement with or without cause upon written notice. In the event of such termination, (i) all licenses granted to us will terminate except in the case of any sublicensee that was not the cause of the termination, is not in default on its obligations under its sublicense, and that pays any unpaid amounts owed by us under the agreement with respect to the sublicense, and (ii) we may complete any work in progress and sell any completed inventory on hand for a period of time after termination. Biomedical Advanced Research and Development Authority In May 2013, the Company entered into an agreement with BARDA, for the evaluation and development of the Company’s lead product candidate solithromycin for the treatment of bacterial infections in pediatric populations and infections caused by bioterror threat pathogens. The agreement is a cost plus fixed fee development contract, with a base performance segment valued at approximately $17.7 million, and four option work segments that BARDA may request at its sole discretion pursuant to the agreement. If all four option segments are requested, the cumulative value of the agreement, as amended to date, would be approximately $59.2 million. Three of the options are cost plus fixed fee arrangements and one option is a cost sharing arrangement without fixed fee, for which the Company would be responsible for a designated portion of the costs associated with that work segment. If all option segments are requested, this estimated period of performance would be extended until approximately May 23, 2018. The estimated period of performance for the base performance segment is May 24, 2013 through February 29, 2016. BARDA exercised the second option in November 2014. The value of the second option work segment is approximately $16.0 million and the estimated period of performance is November 14, 2014 through November 30, 2016. On February 29, 2016, the Company entered into an amendment to its existing agreement with BARDA, for the evaluation and development of its lead product candidate solithromycin for the treatment of bacterial infections in pediatric populations and infections caused by bioterror threat pathogens, specifically anthrax and tularemia. The amendment evidences the authorization by BARDA of a third option work segment of the agreement. The value of this option work segment is approximately $25.5 million, which is intended to fund a Phase 2/3 study of intravenous, oral capsule and oral suspension formulations of solithromycin in pediatric patients from newborn to 17 years with community acquired bacterial pneumonia. The estimated period of performance for this option work segment is February 2016 through May 2018. This option is a cost sharing arrangement for which the Company will be responsible for an additional designated portion of the costs associated with the work segment. Under the agreement, the Company is reimbursed and recognizes revenue as allowable costs are incurred plus a portion of the fixed-fee earned, excluding the cost sharing option segment. The Company considers fixed-fees under cost reimbursable agreements to be earned in proportion to the allowable costs incurred in performance of the work as compared to total estimated agreement costs, with such costs incurred representing a reasonable measurement of the proportional performance of the work completed. Since inception of the agreement through March 31, 2016, the Company has recognized $28.2 million in revenue under this agreement. The agreement provides the U.S. government the ability to terminate the agreement for convenience or to terminate for default if the Company fails to meet its obligations as set forth in the statement of work. The Company believes that if the government were to terminate the agreement for convenience, the costs incurred through the effective date of such termination and any settlement costs resulting from such termination would be allowable costs. Toyama Chemical Co., Ltd. In May 2013, Cempra Pharmaceuticals, Inc., the Company’s wholly owned subsidiary, entered into a license agreement with Toyama Chemical Co., Ltd. (“Toyama”), whereby the Company licensed to Toyama the exclusive right, with the right to sublicense, to make, use and sell any product in Japan that incorporates solithromycin, the Company’s lead compound, as its sole active pharmaceutical ingredient, or API, for human therapeutic uses, other than for ophthalmic indications or any condition, disease or affliction of the ophthalmic tissues. Toyama also has a nonexclusive license in Japan and certain other countries, with the right to sublicense, to manufacture or have manufactured API for solithromycin for use in manufacturing such products, subject to limitations and obligations of the concurrently executed supply agreement discussed below. Toyama granted the Company certain rights to intellectual property generated by Toyama under the license agreement with respect to solithromycin or licensed products for use with such products outside Japan or with other solithromycin-based products inside or outside Japan. Following execution of the agreement, the Company received a $10.0 million upfront payment from Toyama. Toyama is also obligated to pay the Company up to an aggregate of $60.0 million in milestone payments, depending on the achievement of various regulatory, patent, development and commercial milestones. Under the terms of the license agreement, Toyama must also pay the Company a royalty equal to a low-to-high first double decimal digit percentage of net sales, subject to downward adjustment in certain circumstances. In August 2014, the Company received a $10.0 million milestone payment from Toyama (“August 2014 Milestone”), which was triggered by Toyama’s progress of its solithromycin clinical development program in Japan. The payment was made following Toyama’s receipt of regulatory acceptance to begin a Phase 2 trial of solithromycin in Japan following successful completion of a Phase 1 trial. In March 2015, the Company recognized a $10.0 million milestone from Toyama based on the Japan Patent Office issuing a Decision of Allowance for the Company’s patent covering certain crystal forms of solithromycin in Japan, which payment was received in April 2015. As part of the license agreement, Toyama and the Company also entered into a supply agreement, whereby the Company will be the exclusive supplier (with certain limitations) to Toyama and its sublicensees of API for solithromycin for use in licensed products in Japan, as well as the exclusive supplier to Toyama and its sublicensees of finished forms of solithromycin to be used in Phase 1 and Phase 2 clinical trials in Japan. Pursuant to the supply agreement, which is an exhibit to the license agreement, Toyama will pay the Company for such clinical supply of finished product and all supplies of API for solithromycin for any purpose, other than the manufacture of products for commercial sale in Japan, at prices equal to the Company’s cost . The Company has determined that there are six deliverables under this agreement including (1) the license to develop and commercialize solithromycin in Japan, (2) the obligation of the Company to conduct Phase 3 studies and obtain regulatory approval in the United States and one other territory, (3) participation in a Joint Development Committee, or JDC, (4) participation in a Joint Commercialization Committee, or JCC, (5) the right to use the Company’s trademark, and (6) a supply agreement. The amounts received under the license agreement have been allocated to the deliverables based on their relative fair values and will be recognized into income when the revenue recognition criteria have been achieved. Milestone payments are recognized when earned, provided that (i) the milestone event is substantive; (ii) there is no ongoing performance obligation related to the achievement of the milestone earned; and (iii) it would result in additional payments. Milestone payments are considered substantive if all of the following conditions are met: the milestone payment is non-refundable; achievement of the milestone was not reasonably assured at the inception of the arrangement; substantive effort is involved to achieve the milestone; and the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement, and the related risk associated with the achievement of the milestone. Contingent-based payments the Company may receive under a license agreement will be recognized when received. Royalties are recorded as earned in accordance with the contract terms when third party sales can be reliably measured and collectability is reasonably assured. The Company recognized $4.3 million in revenue associated with the delivery of the license in May 2013. Additionally, because the milestone event triggering the August 2014 Milestone payment was considered non-substantive for accounting purposes, this milestone payment is being recognized into revenue proportionately to the six deliverables in the agreement using the same allocation as the upfront payment. Therefore, $4.3 million of the August 2014 milestone payment was recognized into revenue in August 2014. The remainder of the upfront and milestone payments which aggregate to $11.3 million are recorded as deferred revenue at March 2016 and will be recognized as revenue when the revenue recognition criteria of each deliverable has been met. The Company also recognized a $10.0 million milestone based on the Japan Patent Office issuing a Decision of Allowance for the Company’s patent covering certain crystal forms of solithromycin in Japan. FUJIFILM Finechemicals Co., Ltd . On January 18, 2016, Cempra Pharmaceuticals, Inc. entered into an API manufacturing and supply agreement with FUJIFILM Finechemicals Co., Ltd. (“FFFC”), which will provide the Company with solithromycin in sufficient quantities and at reasonable prices to help ensure it meets its obligation under the May 8, 2013 supply agreement with Toyama. The Company will use reasonable efforts to ensure that the solithromycin supplied by FFFC is for use as the active pharmaceutical ingredient in a human drug product to be used or sold in Japan. The Company is subject to a minimum purchase obligation for a designated number of years after the successful completion of the manufacturing facility and validation studies by FFFC. Each calendar month, the Company will submit to FFFC a projection of the anticipated volume of solithromycin that it will order for the next designated period (as set forth in the agreement) (or, if earlier, the final calendar month of the current term). Several months of each forecast are binding and the remaining months are non-binding, provided that the quantity of solithromycin ordered for any month is between designated percentages of the quantity specified in the initial forecast and between designated percentages of the most recent previous forecast. The price of each shipment of solithromycin will be equal to the total number of kilograms in such shipment multiplied by the per-kilogram transfer price as set forth in the agreement. For the term of the agreement plus an additional five years or until the expiration of the patents identified in the agreement, FFFC is prohibited from supplying, selling or distributing solithromycin to, or enabling the manufacture of solithromycin by, any third party for any purpose. The Company is not precluded from developing one or more alternative or additional sources of solithromycin. The agreement’s initial term runs until December 16, 2025. After the end of the initial term, and at the end of each year thereafter, the term will automatically extend for an additional year unless either party gives written notice to the other of its intent to terminate within a designated period of time prior to the expiration of the term, in which case the agreement will terminate at the end of such term. The parties may at any time terminate the agreement by mutual written consent. Each party has the right to terminate the agreement immediately if there is a product failure, the other party becomes involved in bankruptcy, insolvency or similar proceedings or materially breaches the agreement and such breach remains uncured for a period of time following notice of the breach. A violation by the Company of the minimum purchase obligation is considered a material breach. The Company has the right to terminate the agreement upon written notice if there is a supply failure. The Company also may terminate in the event that FFFC cannot provide the Company with solithromycin for more than a designated period of time. Upon termination, any unfulfilled binding portion of the forecast must be delivered by FFFC and paid for by the Company. The Company also may elect to purchase the remaining inventory of FFFC’s solithromycin and any remaining raw materials. If FFFC terminates the agreement for a material breach by the Company and, prior to such termination, (i) FFFC has constructed a facility in Japan for the primary purpose of manufacturing API for the Company under the agreement and (ii) such facility is completed and fully operational and qualified for the manufacture of API for delivery thereunder, then, except to the extent otherwise agreed to by the parties, the Company will pay FFFC an amount equal to (a) the remaining book value of the facility less (b) the product of the number of kilograms of API ordered by the Company under the agreement prior to such termination times a designated dollar amount, provided that if the total direct costs incurred by FFFC in the construction of the facility, net of any tax credits, tax refunds, government subsidies, or similar financial, monetary, or in-kind benefits provided by any governmental agency or authority, do not equal or exceed a designated dollar amount, then the remaining book value will be reduced by a pro rata amount, based on ratios set forth in the agreement, and (z) no amount will be payable if the agreement terminates after December 31, 2025; provided, however, that if FFFC manufactures any product or performs any activities (other than the manufacture of API for the Company under the agreement) in, by, or using the facility prior to such termination and makes any profit thereby, the total amount of such profits well be subtracted from the total payment amount due from the Company to FFFC. Macrolide Pharmaceuticals, Inc. On January 29, 2016, Cempra Pharmaceuticals, Inc. entered into an Option and License Agreement with Macrolide Pharmaceuticals, Inc. (“MP”), pursuant to which MP granted the Company an exclusive option to license certain of MP’s patents and know-how involving macrolides, including specifically novel methods of synthesizing solithromycin (the “Compound”). Under the agreement, the Company will support research at MP focused on developing a novel, cost-competitive manufacturing approach to solithromycin. The option will run until the later to occur of (i) the earlier of (a) the date that the Company first obtains FDA approval for any product incorporating the Compound as an active pharmaceutical ingredient, or API, or (b) January 27, 2019, or (ii) the date that is six months after the earlier of (a) MP’s satisfaction of certain milestones, or (b) the Company’s termination of MP’s obligations under the evaluation program. Under the evaluation program called for in the agreement, MP will conduct research activities for the manufacture of the Compound, which activities the Company will evaluate to determine whether to exercise the option to license. Upon execution of the agreement, the Company paid MP a non-refundable, non-creditable initial license fee of $375,000. For conducting the evaluation program, the Company paid MP a non-refundable, non-creditable fee in the amount of $375,000. In addition, the Company will pay MP the expected reasonable, documented, direct compensation-related costs of employees and advisors necessary to conduct MP’s portion of the evaluation program in the aggregate amount of $1.5 million, which the Company will pay in 18 equal consecutive non-refundable, non-creditable monthly installments of $83,333, beginning with the first monthly anniversary of entry into the agreement. Further, the Company will pay MP up to an aggregate of $1.0 million upon the satisfaction of certain performance milestones. If the Company exercises the option, the license will be exclusive and worldwide (other than Association of Southeast Asian Nations) and for any and all uses in human and non-human animals, and with the right to sublicense. The Company may, in its discretion, exercise the option for a reduced portion of the territory and, if the Company has elected a reduction the territory, may increase as it wishes within the territory, and as many times as it wishes, provided such increase is made within 60 months of the Company’s exercise of the option. If the Company exercises the option, it will pay MP a non-refundable, non-creditable license fee of $1.0 million, of which $500,000 will be paid within 15 business days of exercise, and $500,000 will be paid in the form of “deemed royalty” payments (up to such amount) equal to a fraction of a percent of net sales of licensed products. The Company will pay tiered royalties of a fraction of a percent on designated levels of annual net sales of license products. Further, the Company will pay a non-refundable, non-creditable additional royalty equal to a fraction of a percent on the net sales of licensed products of a designated amount sold by the Company, its sublicensees, and product partners, but the royalty will not exceed $1.0 million in the aggregate. Royalties will be paid on a country-by-country basis and product-by-product basis until the date on which there are no valid claims of any licensed MP patent covering a product in the applicable country. If the Company exercises the option, the agreement’s term will run on a country by country and product by product basis until the date on which there are no valid claims in the licensed MP patents covering a particular product in a particular country. |
Receivables
Receivables | 3 Months Ended |
Mar. 31, 2016 | |
Receivables [Abstract] | |
Receivables | 5. Receivables Receivables consist of amounts billed and amounts earned but unbilled under the Company’s contract with BARDA. At March 31, 2016, the Company’s receivables consisted primarily of earned but unbilled receivables under the BARDA agreement. |
Prepaid Expenses
Prepaid Expenses | 3 Months Ended |
Mar. 31, 2016 | |
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract] | |
Prepaid Expenses | 6. Prepaid Expenses Prepaid expenses are comprised of the following as of (in thousands): March 31, December 31, 2016 2015 Prepaid insurance $ 675 $ 156 Other prepaid expenses 566 417 Total prepaid expenses $ 1,241 $ 573 |
Furniture, Fixtures and Equipme
Furniture, Fixtures and Equipment | 3 Months Ended |
Mar. 31, 2016 | |
Property Plant And Equipment [Abstract] | |
Furniture, Fixtures and Equipment | 7. Furniture, Fixtures and Equipment Furniture, fixtures and equipment consist of the following as of (in thousands): Useful Life (years) March 31, December 31, 2016 2015 Computer equipment 2 $ 149 $ 209 Software 2 48 63 Furniture 5 40 46 Leasehold improvements 3 31 31 Total furniture, fixtures and equipment 268 349 Less accumulated depreciation (193 ) (259 ) Furniture, fixtures and equipment, net $ 75 $ 90 During the three-month periods ended March 31, 2016 and 2015, the Company recorded $14,858 and $18,158 in depreciation expense, respectively. |
Accrued Expenses
Accrued Expenses | 3 Months Ended |
Mar. 31, 2016 | |
Payables And Accruals [Abstract] | |
Accrued Expenses | 8. Accrued Expenses Accrued expenses are comprised of the following as of (in thousands): March 31, December 31, 2016 2015 Accrued professional fees $ 346 $ 642 Other accrued fees 279 222 Franchise tax 188 436 Accrued interest 103 99 Deferred rent 77 76 Total accrued expenses $ 993 $ 1,475 |
Long-Term Debt
Long-Term Debt | 3 Months Ended |
Mar. 31, 2016 | |
Debt Disclosure [Abstract] | |
Long-Term Debt | 9. Long-term Debt In July 2015, the Company entered into a Loan and Security Agreement (the “Loan and Security Agreement”) with Comerica Bank (“Comerica”). The Loan and Security Agreement provides that the Company may borrow up to $20.0 million in a term loan (the “Term Loan”) and, upon FDA approval of its planned New Drug Application for solithromycin, the Company may also borrow an aggregate amount equal to the lesser of (i) up to 75% of its eligible inventory and 80% of eligible accounts receivable or (ii) $10.0 million (the “Revolver”). After FDA approval of the Company’s planned New Drug Application for solithromycin, the Company may convert the Term Loan to the Revolver, in which event the Revolver would have a maximum amount available to the Company of $25.0 million. The Loan and Security Agreement specifies the criteria for determining eligible inventory and eligible accounts receivable and sets forth ongoing limitations and conditions precedent to the Company’s ability to borrow under the Revolver. The Company granted Comerica a security interest in substantially all of its personal property assets, excluding its intellectual property and its stock in its subsidiaries, to secure its outstanding obligations under the Loan and Security Agreement. The Company is also obligated to comply with various other customary covenants, including, among other things, restrictions on its ability to: dispose of assets, make acquisitions, be acquired, incur indebtedness, grant liens, make distributions to its stockholders, make investments, enter into certain transactions with affiliates, or pay down subordinated debt, subject to specified exceptions. At closing, the Company received the full $20.0 million under the Term Loan and paid a facility fee of $100,000 for the Term Loan and a facility fee of $187,500 for the Revolver. The Company immediately used proceeds from the Term Loan to pay all of its $17.7 million outstanding principal and interest and $1.2 million in end of term and prepayment fees under the loan and security agreement (“December 2011 Note”) with Hercules Technology Growth Capital, Inc. (“Hercules”) and terminated the Hercules Loan. The Company recorded a charge of $328,423 on the early extinguishment of the December 2011 Note. Amounts borrowed under the Term Loan may be repaid and reborrowed at any time without penalty or premium. The Term Loan will be interest-only through April 30, 2016, followed by an amortization period of 36 months of equal monthly payments of principal plus interest, beginning on May 1, 2016 and continuing on the same day of each month thereafter until paid in full. Any amounts borrowed under the Term Loan will bear interest at a floating interest rate equal to the 30 Day LIBOR rate plus 5.2%. Amounts available to be borrowed under the Revolver may also be repaid and reborrowed at any time without penalty or premium prior to December 31, 2017, at which time all advances under the Revolver shall be immediately due and payable in full. Any amounts borrowed under the Revolver will bear interest at the 30 Day LIBOR rate plus 4.2%. Once available, the Revolver is subject to an annual unused facility fee equal of 0.25%. Under the Loan and Security Agreement, the Company is subject to certain covenants including maintaining a minimum unrestricted cash balance of $15.0 million and continuing the development or commercially launching solithromycin. |
Shareholders' Equity
Shareholders' Equity | 3 Months Ended |
Mar. 31, 2016 | |
Equity [Abstract] | |
Shareholders' Equity | 10. Common Stock During January 2016, the Company completed a public offering issuing 4,166,667 shares of common stock, at a price of $24.00 per share, resulting in net proceeds to the Company of approximately $93.8 million after deducting underwriting discounts and expenses of approximately $6.2 million. During the first three months of 2016, the Company issued 35,763 shares of common stock at a weighted average exercise price of $6.70 per share upon the exercise of option grants. During January 2015, the Company completed a public offering issuing 6,037,500 shares of common stock, at a price of $24.50 per share, resulting in net proceeds to the Company of approximately $138.8 million after deducting underwriting discounts, commissions and expenses of approximately $9.1 million. The following table presents common stock reserved for future issuance for the following equity instruments as of March 31, 2016: Warrants to purchase common stock 94,912 Options: Outstanding under the 2006 Stock Plan 490,235 Outstanding under the 2011 Equity Incentive Plan 3,001,496 Available for future grants under the 2011 Equity Incentive Plan 3,302,262 Total common stock reserved for future issuance 6,888,905 |
Stock Option Plans
Stock Option Plans | 3 Months Ended |
Mar. 31, 2016 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |
Stock Option Plans | 11. Stock Option Plans The Company adopted the 2006 Stock Plan in January 2006 (the “2006 Plan”). The 2006 Plan provided for the granting of incentive share options, nonqualified share options and restricted shares to Company employees, representatives and consultants. As of March 31, 2016, there were options for an aggregate of 490,235 shares issued and outstanding under the 2006 Plan. The Company’s board of directors and stockholders adopted the 2011 Equity Incentive Plan in October 2011 (the “2011 Plan”), which authorizes the issuance of up to 6,601,735 shares under the 2011 Plan. As of March 31, 2016, there were 3,302,262 options available under the 2011 Plan for future grant. The 2011 Plan provides for an automatic annual increase in the number of shares of common stock reserved for issuance thereunder in the amount of 4% of the shares of common stock outstanding on December 31 of the preceding year. Upon adoption of the 2011 Plan, the Company eliminated the authorization for any unissued shares previously reserved under the Company’s 2006 Plan. The stock awards previously issued under the 2006 Plan remain in effect in accordance with the terms of the 2006 Plan. The following table summarizes the Company’s 2006 and 2011 Plan activity: Weighted Weighted Average Average Aggregate Number of Exercise Contractual Intrinsic Options Price Term (in years) Value (1) Outstanding - December 31, 2015 2,813,765 $ 12.80 Granted 737,283 29.02 Exercised (35,763 ) 6.70 Forfeited (22,512 ) 25.39 Expired (1,042 ) 23.51 Outstanding - March 31, 2016 3,491,731 16.20 7.54 $ 19,979,490 Exercisable - March 31, 2016 2,001,935 9.94 6.40 $ 18,026,149 Vested and expected to vest at March 31, 2016 (2) 3,389,530 $ 15.91 7.49 $ 19,889,333 (1) Intrinsic value is the excess of the fair value of the underlying common shares as of March 31, 2016 over the weighted-average exercise price. (2) The number of stock options expected to vest takes into account an estimate of expected forfeitures. The following table summarizes certain information about all options outstanding as of March 31, 2016: Options Outstanding Options Exercisable Exercise Price Number of Options Weighted Average Remaining Contractual Term (in years) Number of Options Weighted Remaining Contractual Term (in years) $0.48-$1.43 32,633 0.24 32,633 0.24 $2.09-$2.47 457,602 3.77 457,602 3.77 $6.63-$7.86 855,686 6.52 829,021 6.51 $8.70-$18.61 777,822 8.16 351,670 7.80 $23.51-$43.43 1,367,988 9.26 331,009 8.92 3,491,731 2,001,935 During the three-month periods ended March 31, 2016 and 2015, the Company recorded $2,364,511 and $1,434,944 in share-based compensation expense, respectively. |
Income Taxes
Income Taxes | 3 Months Ended |
Mar. 31, 2016 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | 12. Income Taxes The Company estimates an annual effective tax rate of 0% for the year ending December 31, 2016 as the Company incurred losses for the three-month period ended March 31, 2016 and is forecasting additional losses through the fourth quarter, resulting in an estimated net loss for both financial statement and tax purposes for the year ending December 31, 2016. Therefore, no federal or state income taxes are expected and none have been recorded at this time. Income taxes have been accounted for using the liability method in accordance with FASB ASC 740. Due to the Company’s history of losses since inception, there is not enough evidence at this time and it is not more likely than not that the Company will generate sufficient future income of a nature to utilize the benefits of its net deferred tax assets. Accordingly, the deferred tax assets have been reduced by a valuation allowance, since it has been determined that it is more likely than not that all of the deferred tax assets will not be realized. |
Net Loss Per Share
Net Loss Per Share | 3 Months Ended |
Mar. 31, 2016 | |
Earnings Per Share [Abstract] | |
Net Loss Per Share | 13. Net Loss Per Share Basic and diluted net loss per common share was determined by dividing net loss attributable to common shareholders by the weighted average common shares outstanding during the period. The Company’s potentially dilutive shares, which include warrants and common share options, have not been included in the computation of diluted net loss per share for all periods as the result would be antidilutive. The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as they would be antidilutive: Three Months Ended March 31, 2016 2015 Warrants outstanding 94,912 155,221 Stock options outstanding 3,453,884 3,001,037 3,548,796 3,156,258 |
Basis of Presentation (Policies
Basis of Presentation (Policies) | 3 Months Ended |
Mar. 31, 2016 | |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |
Principles of Consolidation and Basis of Presentation | Principles of Consolidation and Basis of Presentation The accompanying consolidated financial statements include the accounts and results of operations of Cempra and its wholly owned subsidiaries. The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany balances and transactions have been eliminated in consolidation. |
Unaudited Interim Financial Data | Unaudited Interim Financial Data The accompanying interim consolidated financial statements are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the accompanying notes for the year ended December 31, 2015 contained in the Company’s Annual Report on Form 10-K. The unaudited interim consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of March 31, 2016 and the results of operations and cash flows for the three months ended March 31, 2016 and 2015. The December 31, 2015 consolidated balance sheet included herein was derived from audited consolidated financial statements, but does not include all disclosures including notes required by U.S. GAAP for complete financial statements. |
Use of Estimates | Use of Estimates The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. |
Receivables | Receivables Receivables consist of amounts billed and amounts earned but unbilled under the Company’s contract with the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services (“BARDA”). Receivables under the BARDA contract are recorded as qualifying research activities are conducted and invoices from the Company’s vendors are received. Unbilled receivables are also recorded based upon work estimated to be complete for which the Company has not received vendor invoices. The Company carries its accounts receivable at cost less an allowance for doubtful accounts. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance based on its history of collections and write-offs and the current status of all receivables. The Company does not accrue interest on trade receivables. If accounts become uncollectible, they will be written off through a charge to the allowance for doubtful accounts. The Company has not recorded an allowance for doubtful accounts as management believes all receivables are fully collectible. |
Research and Development Expenses | Research and Development Expenses Research and development (“R&D”) expenses include direct and indirect R&D costs. Direct R&D consists principally of external costs, such as fees paid to investigators, consultants, central laboratories and clinical research organizations, including costs incurred in connection with clinical trials, and related clinical trial fees and all employee-related expenses for those employees working in research and development functions, including stock-based compensation for R&D personnel. Indirect R&D costs include insurance or other indirect costs related to the Company’s research and development function to specific product candidates. R&D costs are expensed as incurred. Expenses paid but not yet incurred are recorded in prepaid expenses. The Company expenses pre-approval inventory as R&D until regulatory approval is received. |
Clinical Trial Accruals | Clinical Trial Accruals As part of the process of preparing financial statements, the Company is required to estimate its expenses resulting from its obligation under contracts with vendors and consultants and clinical site agreements in connection with conducting clinical trials. The Company’s objective is to reflect the appropriate clinical trial expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. The Company determines accrual estimates through discussion with applicable personnel and outside service providers as to the progress of trials or the services completed. During the course of a clinical trial, the Company adjusts its rate of clinical trial expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. The Company’s clinical trial accrual is dependent upon the timely and accurate reporting of fee billings and passthrough expenses from contract research organizations and other third-party vendors as well as the timely processing of any change orders from the contract research organizations. |
Revenue Recognition | Revenue Recognition The Company’s revenue generally consists of research related revenue under federal contracts and licensing revenue related to non-refundable upfront fees, milestone payments and royalties earned under license agreements. Revenue is recognized when the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products and/or services has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured. For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has “stand-alone value” to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling prices of each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods and services are delivered, limited to the consideration that is not contingent upon future deliverables. When an arrangement is accounted for as a single unit of accounting, the Company determines the period over which the performance obligations will be performed and revenue recognized. Milestone payments are recognized when earned, provided that (i) the milestone event is substantive; (ii) there is no ongoing performance obligation related to the achievement of the milestone earned; and (iii) it would result in additional payments. Milestone payments are considered substantive if all of the following conditions are met: the milestone payment is non-refundable; achievement of the milestone was not reasonably assured at the inception of the arrangement; substantive effort is involved to achieve the milestone; and the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement, and the related risk associated with the achievement of the milestone. Contingent-based payments the Company may receive under a license agreement will be recognized when received. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2016-09, Compensation-Stock Compensation. The new guidance simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. This guidance is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers. This guidance clarifies the implementation guidance on principal versus agent considerations. This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2017, which is effective for the Company for the year ending December 31, 2018. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s financial statements. In February 2016, the FASB issued ASU 2016-02, Leases. The new guidance will increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers. This new guidance clarifies the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The guidance outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes the most current revenue recognition guidance. This guidance, as amended by ASU 2015-14, is effective for fiscal years and interim periods within those years beginning after December 15, 2017, which is effective for the Company for the year ending December 31, 2018. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s financial statements. |
Prepaid Expenses (Tables)
Prepaid Expenses (Tables) | 3 Months Ended |
Mar. 31, 2016 | |
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract] | |
Components of Prepaid Expenses | Prepaid expenses are comprised of the following as of (in thousands): March 31, December 31, 2016 2015 Prepaid insurance $ 675 $ 156 Other prepaid expenses 566 417 Total prepaid expenses $ 1,241 $ 573 |
Furniture, Fixtures and Equip21
Furniture, Fixtures and Equipment (Tables) | 3 Months Ended |
Mar. 31, 2016 | |
Property Plant And Equipment [Abstract] | |
Summary of Furniture, Fixtures and Equipment | Furniture, fixtures and equipment consist of the following as of (in thousands): Useful Life (years) March 31, December 31, 2016 2015 Computer equipment 2 $ 149 $ 209 Software 2 48 63 Furniture 5 40 46 Leasehold improvements 3 31 31 Total furniture, fixtures and equipment 268 349 Less accumulated depreciation (193 ) (259 ) Furniture, fixtures and equipment, net $ 75 $ 90 |
Accrued Expenses (Tables)
Accrued Expenses (Tables) | 3 Months Ended |
Mar. 31, 2016 | |
Payables And Accruals [Abstract] | |
Accrued Expenses | Accrued expenses are comprised of the following as of (in thousands): March 31, December 31, 2016 2015 Accrued professional fees $ 346 $ 642 Other accrued fees 279 222 Franchise tax 188 436 Accrued interest 103 99 Deferred rent 77 76 Total accrued expenses $ 993 $ 1,475 |
Shareholders' Equity (Tables)
Shareholders' Equity (Tables) | 3 Months Ended |
Mar. 31, 2016 | |
Equity [Abstract] | |
Common Stock Reserved for Future Issuance | The following table presents common stock reserved for future issuance for the following equity instruments as of March 31, 2016: Warrants to purchase common stock 94,912 Options: Outstanding under the 2006 Stock Plan 490,235 Outstanding under the 2011 Equity Incentive Plan 3,001,496 Available for future grants under the 2011 Equity Incentive Plan 3,302,262 Total common stock reserved for future issuance 6,888,905 |
Stock Option Plans (Tables)
Stock Option Plans (Tables) | 3 Months Ended |
Mar. 31, 2016 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |
Share Option Plans | The following table summarizes the Company’s 2006 and 2011 Plan activity: Weighted Weighted Average Average Aggregate Number of Exercise Contractual Intrinsic Options Price Term (in years) Value (1) Outstanding - December 31, 2015 2,813,765 $ 12.80 Granted 737,283 29.02 Exercised (35,763 ) 6.70 Forfeited (22,512 ) 25.39 Expired (1,042 ) 23.51 Outstanding - March 31, 2016 3,491,731 16.20 7.54 $ 19,979,490 Exercisable - March 31, 2016 2,001,935 9.94 6.40 $ 18,026,149 Vested and expected to vest at March 31, 2016 (2) 3,389,530 $ 15.91 7.49 $ 19,889,333 (1) Intrinsic value is the excess of the fair value of the underlying common shares as of March 31, 2016 over the weighted-average exercise price. (2) The number of stock options expected to vest takes into account an estimate of expected forfeitures. |
Options Outstanding | The following table summarizes certain information about all options outstanding as of March 31, 2016: Options Outstanding Options Exercisable Exercise Price Number of Options Weighted Average Remaining Contractual Term (in years) Number of Options Weighted Remaining Contractual Term (in years) $0.48-$1.43 32,633 0.24 32,633 0.24 $2.09-$2.47 457,602 3.77 457,602 3.77 $6.63-$7.86 855,686 6.52 829,021 6.51 $8.70-$18.61 777,822 8.16 351,670 7.80 $23.51-$43.43 1,367,988 9.26 331,009 8.92 3,491,731 2,001,935 |
Net Loss Per Share (Tables)
Net Loss Per Share (Tables) | 3 Months Ended |
Mar. 31, 2016 | |
Earnings Per Share [Abstract] | |
Antidilutive Securities Excluded from Computation of Diluted Weighted Average Shares Outstanding | The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as they would be antidilutive: Three Months Ended March 31, 2016 2015 Warrants outstanding 94,912 155,221 Stock options outstanding 3,453,884 3,001,037 3,548,796 3,156,258 |
Basis of Presentation - Additio
Basis of Presentation - Additional Information (Details) | Mar. 31, 2016USD ($) |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |
Allowance for doubtful accounts receivable recorded | $ 0 |
Fair Value of Financial Instr27
Fair Value of Financial Instruments - Additional Information (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2016 | Dec. 31, 2015 | |
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Transfers between levels of the fair value hierarchy | $ 0 | |
Term Loan | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Carrying value of notes | 19,700,000 | |
Recurring Basis | Money Market Funds | Quoted Prices in Active Markets for Identical Assets (Level 1) | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Assets classified as fair value of financial instruments | $ 223,600,000 | $ 129,000,000 |
Significant Agreements and Co28
Significant Agreements and Contracts - Additional Information (Details) | Jan. 29, 2016USD ($) | Aug. 31, 2014USD ($) | May. 31, 2013USD ($) | Mar. 31, 2015USD ($) | Jul. 31, 2012USD ($) | Jul. 31, 2010USD ($) | Mar. 31, 2016USD ($)ProductSegmentDeliverablesshares | Mar. 31, 2015USD ($) | Jun. 30, 2012USD ($) | Dec. 31, 2015USD ($) |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||
Contract research | $ 2,679,000 | $ 2,077,000 | ||||||||
Deferred revenue | $ 11,326,000 | $ 11,326,000 | ||||||||
Optimer Pharmaceuticals Inc | Collaborative Arrangement | ||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||
Common shares issued to Optimer in exchange for license | shares | 125,646 | |||||||||
Fair value of common shares issued to Optimer | $ 190,418 | |||||||||
Milestone payment paid to Optimer | $ 1,000,000 | $ 500,000 | ||||||||
Aggregate amount of milestone payment | $ 27,500,000 | |||||||||
Number of products required to be developed through FDA approval | Product | 4 | |||||||||
Royalty payment based on annual net sales description | The Company will also pay tiered mid-single-digit royalties based on the amount of annual net sales of its approved products. | |||||||||
The Scripps Research Institute | ||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||
Royalty payment based on annual net sales description | Under the terms of the agreement, the Company must pay TSRI low single-digit percentage royalties on the net sales of the products covered by the TSRI patents for the life of the TSRI patents, a low single-digit percentage of non-royalty sublicensing revenue received with respect to countries in the nonexclusive territory and a mid-single-digit percentage of sublicensing revenue received with respect to countries in the exclusive territory, with the sublicensing revenue royalty in the exclusive territory and the sales royalties subject to certain reductions under certain circumstances. | |||||||||
Non refundable license issue fee | $ 350,000 | |||||||||
Eligible milestone payment | $ 1,100,000 | |||||||||
Sublicense fees paid | 200,000 | |||||||||
The Scripps Research Institute | First Three Years | ||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||
Annual maintenance fees | 50,000 | |||||||||
The Scripps Research Institute | Fourth Through Six Years | ||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||
Annual maintenance fees | 85,000 | |||||||||
Biomedical Advanced Research and Development Authority | ||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||
Value of cost plus fixed fee development contract with base performance segment | $ 17,700,000 | |||||||||
Number of option work segments | Segment | 4 | |||||||||
Cumulative value of cost plus fixed fee development contract with base performance segment of four option work segments | $ 59,200,000 | |||||||||
Number of options under cost plus fixed fee arrangements | Segment | 3 | |||||||||
Number of options under cost sharing arrangement without fixed fee | Segment | 1 | |||||||||
Aggregate milestone payments receivable under license agreement | May 24, 2013 | |||||||||
Estimated period of performance for the base performance segment ending date | Feb. 29, 2016 | |||||||||
Extended estimated period of performance for the base performance segment | May 23, 2018 | |||||||||
Contract research | $ 28,200,000 | |||||||||
Biomedical Advanced Research and Development Authority | Second Option Work | ||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||
Value of cost plus fixed fee development contract with base performance segment | $ 16,000,000 | |||||||||
Aggregate milestone payments receivable under license agreement | Nov. 14, 2014 | |||||||||
Estimated period of performance for the base performance segment ending date | Nov. 30, 2016 | |||||||||
Biomedical Advanced Research and Development Authority | Third Option Work | ||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||
Value of cost plus fixed fee development contract with base performance segment | $ 25,500,000 | |||||||||
Aggregate milestone payments receivable under license agreement | Feb. 29, 2016 | |||||||||
Estimated period of performance for the base performance segment ending date | May 31, 2018 | |||||||||
Toyama Chemical | ||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||
Contract research | $ 6,100,000 | |||||||||
Deferred revenue | $ 10,000,000 | $ 11,300,000 | ||||||||
Aggregate milestone payments | 60,000,000 | |||||||||
Milestone payment amount received | $ 10,000,000 | |||||||||
Number of deliverables under license agreement | Deliverables | 6 | |||||||||
Milestone payment recognized as revenue | $ 4,300,000 | $ 4,300,000 | $ 10,000,000 | |||||||
Supply agreement date | May 8, 2013 | |||||||||
FUJIFILM Finechemicals Co., Ltd. | ||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||
Manufacturing and supply agreement date | Jan. 18, 2016 | |||||||||
Prohibition term | For the term of the agreement plus an additional five years or until the expiration of the patents identified in the agreement, FFFC is prohibited from supplying, selling or distributing solithromycin to, or enabling the manufacture of solithromycin by, any third party for any purpose. The Company is not precluded from developing one or more alternative or additional sources of solithromycin. | |||||||||
Aggregate initial term of agreement | Dec. 16, 2025 | |||||||||
Macrolide Pharmaceuticals Inc | ||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||
Non refundable license issue fee | $ 375,000 | |||||||||
Option and license agreement | Jan. 29, 2016 | |||||||||
License agreement description | The option will run until the later to occur of (i) the earlier of (a) the date that the Company first obtains FDA approval for any product incorporating the Compound as an active pharmaceutical ingredient, or API, or (b) January 27, 2019, or (ii) the date that is six months after the earlier of (a) MP’s satisfaction of certain milestones, or (b) the Company’s termination of MP’s obligations under the evaluation program. | |||||||||
Aggregate amount of compensation related cost | $ 1,500,000 | |||||||||
Compensation related cost payment installment term | 18 months | |||||||||
Compensation related cost monthly installment amount | $ 83,333 | |||||||||
Duration of increase made in territory of exercise of option | 60 months | |||||||||
Non-refundable, non-creditable license fee | $ 1,000,000 | |||||||||
Amount of license fee payable upon exercise | 500,000 | |||||||||
Deemed royalty payments | 500,000 | |||||||||
Aggregate amount of royalty | 1,000,000 | |||||||||
Macrolide Pharmaceuticals Inc | License Fee Paid | ||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||
Non refundable license issue fee | 375,000 | |||||||||
Macrolide Pharmaceuticals Inc | Maximum | ||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||
Aggregate amount of milestone payment | $ 1,000,000 |
Prepaid Expenses - Components o
Prepaid Expenses - Components of Prepaid Expenses (Details) - USD ($) $ in Thousands | Mar. 31, 2016 | Dec. 31, 2015 |
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract] | ||
Prepaid insurance | $ 675 | $ 156 |
Other prepaid expenses | 566 | 417 |
Total prepaid expenses | $ 1,241 | $ 573 |
Furniture, Fixtures and Equip30
Furniture, Fixtures and Equipment - Summary of Furniture, Fixtures and Equipment (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2016 | Dec. 31, 2015 | |
Property Plant And Equipment [Line Items] | ||
Total furniture, fixtures and equipment | $ 268 | $ 349 |
Less accumulated depreciation | (193) | (259) |
Furniture, fixtures and equipment, net | $ 75 | 90 |
Computer Equipment | ||
Property Plant And Equipment [Line Items] | ||
Useful Life (years) | 2 years | |
Total furniture, fixtures and equipment | $ 149 | 209 |
Software | ||
Property Plant And Equipment [Line Items] | ||
Useful Life (years) | 2 years | |
Total furniture, fixtures and equipment | $ 48 | 63 |
Furniture | ||
Property Plant And Equipment [Line Items] | ||
Useful Life (years) | 5 years | |
Total furniture, fixtures and equipment | $ 40 | 46 |
Leasehold Improvements | ||
Property Plant And Equipment [Line Items] | ||
Useful Life (years) | 3 years | |
Total furniture, fixtures and equipment | $ 31 | $ 31 |
Furniture, Fixtures and Equip31
Furniture, Fixtures and Equipment - Additional Information (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2016 | Mar. 31, 2015 | |
Property Plant And Equipment [Abstract] | ||
Depreciation expense | $ 14,858 | $ 18,158 |
Accrued Expenses - Accrued Expe
Accrued Expenses - Accrued Expenses (Details) - USD ($) $ in Thousands | Mar. 31, 2016 | Dec. 31, 2015 |
Accrued expenses | ||
Accrued professional fees | $ 346 | $ 642 |
Other accrued fees | 279 | 222 |
Franchise tax | 188 | 436 |
Accrued interest | 103 | 99 |
Deferred rent | 77 | 76 |
Total accrued expenses | $ 993 | $ 1,475 |
Long-Term Debt - Additional Inf
Long-Term Debt - Additional Information (Details) - USD ($) | 1 Months Ended | 3 Months Ended |
Jul. 31, 2015 | Mar. 31, 2016 | |
Loan and Security Agreement | ||
Debt Instrument [Line Items] | ||
Minimum unrestricted cash balance requirement | $ 15,000,000 | |
Loan and Security Agreement | Term Loan | ||
Debt Instrument [Line Items] | ||
Loan and security agreement | $ 20,000,000 | |
Eligible inventory percentage for additional borrowings | 75.00% | |
Eligible accounts receivable for additional borrowings | 80.00% | |
Proceeds received from the agreement | $ 20,000,000 | |
Facility fee paid for the credit facility | $ 100,000 | |
End date of interest-only payment | Apr. 30, 2016 | |
Amortization period of principal and interest payments | 36 months | |
Description of variable rate basis | 30 Day LIBOR | |
Beginning date for principal plus interest payment | May 1, 2016 | |
Loan and Security Agreement | Term Loan | LIBOR | ||
Debt Instrument [Line Items] | ||
Basis spread on variable rate | 5.20% | |
Loan and Security Agreement | Revolver | ||
Debt Instrument [Line Items] | ||
Loan and security agreement | $ 10,000,000 | |
Maximum borrowing capacity if term loans are converted | 25,000,000 | |
Facility fee paid for the credit facility | $ 187,500 | |
Description of variable rate basis | 30 Day LIBOR | |
Last date for repayment and reborrowed without penalty or premium | Dec. 31, 2017 | |
Annual unused facility fee percentage | 0.25% | |
Loan and Security Agreement | Revolver | LIBOR | ||
Debt Instrument [Line Items] | ||
Basis spread on variable rate | 4.20% | |
December 2011 Note | ||
Debt Instrument [Line Items] | ||
Long-term debt, borrowed | $ 17,700,000 | |
Term and prepayment fees | 1,200,000 | |
Charge recorded on early extinguishment of debt | $ (328,423) |
Shareholders' Equity - Addition
Shareholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions | 1 Months Ended | 3 Months Ended | |
Jan. 31, 2016 | Jan. 31, 2015 | Mar. 31, 2016 | |
Shareholders' Equity (Deficit) (Textual) [Abstract] | |||
Issuance of common shares upon exercise of options, shares | 35,763 | ||
Weighted average exercise price of common stock | $ 6.70 | ||
Common Stock | |||
Shareholders' Equity (Deficit) (Textual) [Abstract] | |||
Number of common stocks issued through public offering | 4,166,667 | 6,037,500 | |
Common share price | $ 24 | $ 24.50 | |
Proceeds from issuance of common stock, net of underwriting discounts and offering costs | $ 93.8 | $ 138.8 | |
Underwriting discounts and commissions, and expenses | $ 6.2 | $ 9.1 | |
Issuance of common shares upon exercise of options, shares | 35,763 | ||
Weighted average exercise price of common stock | $ 6.70 |
Shareholders' Equity - Common S
Shareholders' Equity - Common Stock Reserved for Future Issuance (Details) | Mar. 31, 2016shares |
Class Of Stock [Line Items] | |
Common stock reserved for future issuance | 6,888,905 |
Warrants to purchase common stock | |
Class Of Stock [Line Items] | |
Common stock reserved for future issuance | 94,912 |
Options Outstanding | 2006 Stock Plan | |
Class Of Stock [Line Items] | |
Common stock reserved for future issuance | 490,235 |
Options Outstanding | 2011 Equity Incentive Plan | |
Class Of Stock [Line Items] | |
Common stock reserved for future issuance | 3,001,496 |
Options Available For Future Grants | 2011 Equity Incentive Plan | |
Class Of Stock [Line Items] | |
Common stock reserved for future issuance | 3,302,262 |
Stock Option Plans - Additional
Stock Option Plans - Additional Information (Details) - USD ($) | 3 Months Ended | |||
Mar. 31, 2016 | Mar. 31, 2015 | Dec. 31, 2015 | Oct. 31, 2011 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Options for shares issued and outstanding | 3,491,731 | 2,813,765 | ||
Share-based compensation | $ 2,364,511 | $ 1,434,944 | ||
Unrecognized compensation cost | $ 21,281,758 | |||
Expected weighted average recognition period, Unvested shares | 2 years 11 months 27 days | |||
2006 Stock Plan | ||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Options for shares issued and outstanding | 490,235 | |||
2011 Equity Incentive Plan | ||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Maximum number of shares authorized for future issuances | 6,601,735 | |||
Options shares available under the 2011 Plan | 3,302,262 | |||
Percent of annual increase in share reserved for future issuance | 4.00% |
Stock Option Plans - Share Opti
Stock Option Plans - Share Option Plans (Details) | 3 Months Ended |
Mar. 31, 2016USD ($)$ / sharesshares | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |
Number of Options, Outstanding | shares | 2,813,765 |
Number of Options, Granted | shares | 737,283 |
Number of Options, Exercised | shares | (35,763) |
Number of Options, Forfeited | shares | (22,512) |
Number of Options, Expired | shares | (1,042) |
Number of Options, Outstanding | shares | 3,491,731 |
Number of Options, Exercisable | shares | 2,001,935 |
Number of Options, Vested and expected to vest | shares | 3,389,530 |
Weighted Average Exercise Price, Outstanding | $ / shares | $ 12.80 |
Weighted Average Exercise Price, Granted | $ / shares | 29.02 |
Weighted Average Exercise Price, Exercised | $ / shares | 6.70 |
Weighted Average Exercise Price, Forfeited | $ / shares | 25.39 |
Weighted Average Exercise Price, Expired | $ / shares | 23.51 |
Weighted Average Exercise Price, Outstanding | $ / shares | 16.20 |
Weighted Average Exercise Price, Exercisable | $ / shares | 9.94 |
Weighted Average Exercise Price, Vested and expected to vest | $ / shares | $ 15.91 |
Weighted Average Contractual Term (in years), Outstanding | 7 years 6 months 15 days |
Weighted Average Contractual Term (in years), Exercisable | 6 years 4 months 24 days |
Weighted Average Contractual Term (in years), Vested and expected to vest | 7 years 5 months 27 days |
Aggregate Intrinsic Value, Outstanding | $ | $ 19,979,490 |
Aggregate Intrinsic Value, Exercisable | $ | 18,026,149 |
Aggregate Intrinsic Value, Vested and expected to vest | $ | $ 19,889,333 |
Stock Option Plans - Options Ou
Stock Option Plans - Options Outstanding (Details) - $ / shares | 3 Months Ended | |
Mar. 31, 2016 | Dec. 31, 2015 | |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Number of Options Outstanding | 3,491,731 | 2,813,765 |
Number of Options, Exercisable | 2,001,935 | |
Exercise Price $0.48 - $1.43 | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise price range lower range limit | $ 0.48 | |
Exercise price range upper range limit | $ 1.43 | |
Number of Options Outstanding | 32,633 | |
Weighted Average Remaining Contractual Term (in years), Outstanding | 2 months 27 days | |
Number of Options, Exercisable | 32,633 | |
Weighted Average Remaining Contractual Term (in years), Exercisable | 2 months 27 days | |
Exercise Price $2.09 - $2.47 | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise price range lower range limit | $ 2.09 | |
Exercise price range upper range limit | $ 2.47 | |
Number of Options Outstanding | 457,602 | |
Weighted Average Remaining Contractual Term (in years), Outstanding | 3 years 9 months 7 days | |
Number of Options, Exercisable | 457,602 | |
Weighted Average Remaining Contractual Term (in years), Exercisable | 3 years 9 months 7 days | |
Exercise Price $6.63 - $7.86 | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise price range lower range limit | $ 6.63 | |
Exercise price range upper range limit | $ 7.86 | |
Number of Options Outstanding | 855,686 | |
Weighted Average Remaining Contractual Term (in years), Outstanding | 6 years 6 months 7 days | |
Number of Options, Exercisable | 829,021 | |
Weighted Average Remaining Contractual Term (in years), Exercisable | 6 years 6 months 4 days | |
Exercise Price $8.70 - $18.61 | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise price range lower range limit | $ 8.70 | |
Exercise price range upper range limit | $ 18.61 | |
Number of Options Outstanding | 777,822 | |
Weighted Average Remaining Contractual Term (in years), Outstanding | 8 years 1 month 28 days | |
Number of Options, Exercisable | 351,670 | |
Weighted Average Remaining Contractual Term (in years), Exercisable | 7 years 9 months 18 days | |
Exercise Price $23.51-$43.43 | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise price range lower range limit | $ 23.51 | |
Exercise price range upper range limit | $ 43.43 | |
Number of Options Outstanding | 1,367,988 | |
Weighted Average Remaining Contractual Term (in years), Outstanding | 9 years 3 months 4 days | |
Number of Options, Exercisable | 331,009 | |
Weighted Average Remaining Contractual Term (in years), Exercisable | 8 years 11 months 1 day |
Income Taxes - Additional Infor
Income Taxes - Additional Information (Details) | 3 Months Ended |
Mar. 31, 2016USD ($) | |
Income Tax Contingency [Line Items] | |
Effective tax rate | 0.00% |
U.S. Federal or State Income Tax | |
Income Tax Contingency [Line Items] | |
Income tax expense | $ 0 |
Net Loss Per Share - Antidiluti
Net Loss Per Share - Antidilutive Securities Excluded from Computation of Diluted Weighted Average Shares Outstanding (Details) - shares | 3 Months Ended | |
Mar. 31, 2016 | Mar. 31, 2015 | |
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of diluted weighted average shares outstanding | 3,548,796 | 3,156,258 |
Warrants to purchase common stock | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of diluted weighted average shares outstanding | 94,912 | 155,221 |
Stock Options | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of diluted weighted average shares outstanding | 3,453,884 | 3,001,037 |